Compare IMXI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | CELC |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 4.2B |
| IPO Year | 2016 | 2017 |
| Metric | IMXI | CELC |
|---|---|---|
| Price | $12.10 | $81.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $15.00 | ★ $112.56 |
| AVG Volume (30 Days) | 357.6K | ★ 755.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $319,601,000.00 | N/A |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | $720.19 |
| P/E Ratio | $84.13 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $11.15 | $44.42 |
| 52 Week High | $15.95 | $151.02 |
| Indicator | IMXI | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 30.23 | 37.66 |
| Support Level | $11.21 | $78.60 |
| Resistance Level | $14.77 | $96.39 |
| Average True Range (ATR) | 0.32 | 3.55 |
| MACD | -0.24 | -0.94 |
| Stochastic Oscillator | 7.33 | 6.33 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.